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THE PROBLEM, THERE IS
ALWAYS A SIMPLE
SOLUTION—WHICH IS
WRONG!
To the Editor:
Is it the cough that carries them off?
Asbestos-related pulmonary dis-
ease, and specifically the development
of mesothelioma, continues to be
a tragic health issue. There are charac-
teristics of thewhole disease entity that
seem both unusual but interrelated.
The inhalation of relatively long asbes-
tos fibers is followed by their transport
to the visceral pleura and subsequently
to the parietal pleura and, via lym-
phatics, elsewhere. The fibers produce
subpleural fibrosis in the lungs, but this
discussion relates to the moreThe Journalsignificant parietal pleural changes.
Usually, the first and most diagnostic
appearance is that of pleural plaques,
with or without calcification, at chest
radiograph or computed tomographic
scan. There are several features of
these that warrant consideration.
1. They involve the parietal pleura
and not the visceral.
2. They arise in areas of greatest
movement between the opposing
pleural layers, with respiration,
coughing, and sneezing. They do
not occur over the lung apices or
within the interlobar fissures where
the pleural surfacesmove in unison.
3. The plaques and calcifications tend
to group deep to the ribs. And yes,
some also form over the diaphragm
and pericardium.
A simple question then arises—Is the
development of pleural plaques and
subsequent mesothelioma a result of
chronic abrasive trauma caused by
these fibers at the visceral surface
abraiding the parietal pleura, akin to
oral tumors resulting from ‘‘ill fitting
dentures?’’ This would then infer a me-
chanical etiology rather than a chemical
carcinogenesis and perhaps explain
why other fibers with similar physical
characteristics have also been impli-
catedor areunder suspicion.Of interest,
talc had been viewed with suspicion by
some because of its fiber structure, but
the fact that it produces pleurodesis
would negate any such effect.
If this hypothesis is worthy of con-
sideration, several other points arise.
The negative pressure within the
pleural cavity during quiet respiration,
maintaining the apposition of the vis-
ceral and parietal pleural layers, is
very low, and thiswouldby inference re-
duce abrasive effects. However, during
coughing the glottis closes while the in-
tercostal muscles and abdominal wall
muscles contract, increasing the intra-
thoracic and intrapleural pressurebefore
there is an explosive release of air from
the chest. Themarkedly increaseddirect
pressure exerted by the ribs on the un-
derlying pleural space may explain theof Thoracic and Cardiovascular Surgeapparent predilection of pleural plaques
for these regions.
If these suppositions hold weight,
then an obvious question arises. Is
there a place for prophylactic pleurod-
esis in the prevention of mesothelioma
by preventing chronic abrasion be-
tween the pleural surfaces?
The risk of development of meso-
thelioma in those with asbestos-
related disease has been quoted at
10%, a figure presumably subject to
much discussion. It may be arguable
whether even a procedure of low mor-
bidity should be universally proposed
as a panacea. However, other factors,
possibly including plaque load, life
expectancy, smoking, and chronic
cough, may enable identification of
higher risk groups for whom active in-
tervention may be justified.
Vincent Acton, FRANZCR
Sydney, Australia
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MEDIASTINAL LYMPH NODES
To the Editor:
We read with great interest the re-
sults of the American College of Sur-
gery Oncology Group (ACOSOG)
Z0030 trial,1 which was a randomized,
multi-institutional, prospective trial of
mediastinal lymph node dissection
(MLND) versus sampling (MLNS)
during pulmonary resection for pa-
tients with early-stage (N0 or nonhilar
N1, T1, or T2) non–small cell lung can-
cer (NSCLC). At a median follow-up
of 6.5 years, 44% died in the MLNS
arm and 42% died in the MLND arm,
and the median survival was 8.1 years
in the MLNS group and 8.5 years in
theMLNDgroup (P¼ .25). Studies ad-
dressing the survival benefit ofMLND,
however, have been inconclusive.
We herein performed a meta-analysis
of randomized controlled trials of
MLND versus MLNS during pulmo-
nary resection for prevention of all-
cause mortality in early-stage NSCLC.ry c Volume 142, Number 2 477
FIGURE 1. All cause mortality (A, risk ratio; B, hazard ratio) among patients with early-stage non-small cell lung cancer randomized to mediastinal lymph
node dissection (MLND) versus sampling (MLNS) during pulmonary resection. IV, Inverse variance;CI, confidence interval; ACOSOG,American College of
Surgery Oncology Group; SE, standard error.
Letters to the EditorStudies considered for inclusion met
the following criteria: the design was
a prospective randomized controlled
clinical trial; the study population was
patients with early-stage (stage I–IIIA)
NSCLC; patients were randomly as-
signed to MLND versus MLNS during
pulmonary resection; and main out-
comes included follow-up all-cause
mortality.For each study, data regarding
all-cause mortality in both the MLND
and MLNS groups were used to gener-
ate risk ratios (RRs) and 95% confi-
dence intervals (CIs). Hazard ratios
(HRs) for all-cause death and 95%
CIswere also abstracted fromeach indi-
vidual study. Study-specific estimates
were combined using inverse variance-
weighted averages of logarithmic RRs
or HRs in both fixed- and random-
effects models. Where no significant
statistical heterogeneity was identified,
the fixed-effect estimate was used pref-
erentially as the summary measure.
Our comprehensive search (current
through March 2011) identified 4 trials:
median6.5-year results of theACOSOG
Z0030 trial,1 10-year results of a trial by
Wu and associates,2median 5.4-year re-
sults of a trial by Sugi and colleagues,3
and median 4.0-year results of a trial
by Izbicki and collaborators.4 Pooled
analysis of the 4 trials (representing478 The Journal of Thoracic and C1778 patients with early-stage NSCLC)
demonstrated a statistically nonsignifi-
cant reduction (but a strong trend toward
a significant reduction) in all-causemor-
tality with MLND relative to MLNS in
fixed-effects models (RR, 0.91; 95%
CI, 0.82-1.00; P ¼ .05; P for heteroge-
neity ¼ .59 [Figure 1, A]; HR, 0.86;
95% CI, 0.73-1.01; P¼ .06; P for het-
erogeneity ¼ .29 [Figure 1, B]). Exclu-
sion of any single trial of the previous
3 trials2-4 from the analysis did not sub-
stantively alter the overall result of our
analysis. Eliminating the ACOSOG
Z0030 trial,1 however, demonstrated
a statistically significant reduction in
all-cause mortality withMLND relative
to MLNS (RR, 0.87; 95% CI, 0.76-
0.99; P ¼ .04; HR, 0.69; 95% CI,
0.51-0.93; P¼ .01).
The results of the present analysis
suggest that MLND may not reduce
all-cause mortality over MLNS during
pulmonary resection in patients with
early-stage NSCLC. The results are
not robust, however, because exclu-
sion of the ACOSOG Z0030 trial1
substantially changed the pooled esti-
mate. Which way we ought to walk
from here depends a good deal on
where we want to get to.
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doi:10.1016/j.jtcvs.2011.03.032Reply to the Editor:
We read with interest the letter of
Takagi, Matsui, and Umemoto, who
provided the results of their meta-
analyses of randomized controlled tri-
als of mediastinal lymph node
